Key facts
- It has raised $5.3M; the latest was Early Stage VC ($5.3M) in Feb 2026.
- Notable investors include Science Ventures, Syddansk Universitet.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Crossingbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Crossingbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Crossingbio
Developer of antibody-based therapeutics intended to treat fibrotic diseases by targeting proteins involved in fibrosis development. The company offers antibody therapeutics, targeting antibodies, fibrosis drug candidates, fibrosis research programs, preclinical disease models, and clinical development programs, enabling researchers and healthcare developers to investigate protein-targeted treatments for liver fibrosis and related fibrotic conditions.
- Sector
- Healthcare
- HQ
- Odense, Denmark
- Founded
- 2025
- Employees
- 2
- Ownership
- Privately Held (backing)
Crossingbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Crossingbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Crossingbio in its N-PORT filings yet. We sweep new filings monthly.